RCS - Yourgene Health PLC - CQC accreditation

Yourgene HealthAnnouncement

23/10/2020 07:00

RNS Number : 9723C
  
Yourgene Health PLC
  
23 October 2020
  
 

 
Yourgene Health plc
("Yourgene Health" or the "Company")
 
CQC accreditation
 
Manchester, UK - 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission ("CQC") that the Company's facilities at Citylabs 1.0 in Manchester are now a second accredited location from which to perform diagnostics and screening procedures.
 
The extension of the Company's current CQC registration allows NIPT testing greater flexibility to operate from both Yourgene Health locations in Manchester, and confirms that the Company's COVID-19 testing services meet the demanding standards of the CQC. As announced on 28 September 2020, the launch of Yourgene Genomic Services consolidates the Company's established NIPT and rapidly growing COVID-19 testing services in Manchester and this accreditation supports this strategy. The CQC registration supports the Company's continued scale up in capacity for COVID-19 testing for both private and public market segments.
 
The CQC is an independent regulator of health and social care in England and ensures, amongst other things, that services are safe, high-quality, effective and meet legal standards.
 



Yourgene Health plc
Lyn Rees, Chief Executive Officer


Tel: +44 (0)161 669 8122
investors@yourgene-health.com




Barry Hextall, Chief Financial Officer


 




Joanne Cross, Director of Marketing


 




 


 




N+1 Singer (Joint Corporate Broker)


Tel: +44 (0)20 7496 3000




Aubrey Powell / Tom Salvesen / George Tzimas


 




 


 




Stifel Nicolaus Europe Limited (Joint Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


 




 


 




 


 




Walbrook PR Ltd (Media and Investor Relations)


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com




 Paul McManus / Lianne Cawthorne


Mob: 07980 541 893 / Mob: 07584 391 303




 


 


 




 


 









 
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
 
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
 
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
 
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRABLBDGSBDDGGD